Integrity Coronary Stent System    

Log In

Forgot Your Password?

Not a member? Click here!

The Medtronic Ventor EngagerTM TAVI System
William O’Neill, MD, Performs First Transcatheter Triscuspid Valve Replacement in the United States
New Outcomes Study for Ticagrelor (BRILINTA™) to Examine Longer-term Treatment for Post- ACS Patients
Anomalous Left Circumflex Artery from the Right Coronary Cusp: A Benign Variant?
Self-expanding, anatomically correct transapical aortic valve implantation



St. Jude pausing its Portico transcatheter valve study

Deutsche Bank Markets Research has confirmed with St. Jude management that it has decided to pause its global Portico transcatheter valve clinical trials and sales. The decision has been communicated to the FDA, clinical investigators and clinical sites.

For more, click here




What is going to be hot at TCT.14

Transcatheter Cardiovascular Therapeutics (TCT) Scientific session is back in the nation’s capital. From transcatheter valve technologies to the IVUS-guided CTO interventions, from bioabsorbable scaffolds to peritoneal hypothermia in STEMI; there will be a late-breaker to suit all interests at this year’s premier interventional cardiology meeting.

For more, click here




Impaired Responsiveness to Clopidogrel in Type II DM

Patients with diabetes mellitus (DM) may exhibit impaired responsiveness to clopidogrel. A mechanistic study has indicated that this may be mediated by attenuation of clopidogrel’s pharmacokinetic profile characterized by lower levels of the active metabolites of the drug.

For more, click here




Long-Term Mortality Post Venous Thromboembolism

The long-term impact of venous thromboembolism (VTE) is uncertain. A 3-year nationwide population-based cohort study of 128223 patients with first-time VTE has indicated that such patients are at increased risk of dying during the entire follow-up period. The study has also indicated that although the 30-day mortality for DVT has remained constant, it has significantly improved for PE.

For more, click here




AKI & Coronary Revascularization

The incidence of acute kidney injury (AKI) following PCI or CABG is uncertain. A comparative study of patients undergoing multivessel CABG and PCI has indicated that CABG may be associated with a 2-3x fold greater risk of AKI.

For more, click here



Untitled Document
PROTECT Trial: 5 Year Outcomes
- Edoardo Camenzind, MD
Reduction in office blood pressure after renal denervation in a large real world patient population with uncontrolled hypertension: interim 12-month results from the Global SYMPLICITY Registry
- Felix Mahfoud, MD
SYMPLICITY HTN-3 Trial: 12-month outcomes following un-blinding of subjects at 6 months
- George L. Bakris, MD
Aortic Valve-in-Valve: Insights from the Global Registry
- Danny Dvir, MD

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD

 Click here to visit the WEBEX archives

A Systematic Examination of the 2013 ACC/AHA Pooled Cohort Risk Assessment Tool for Atherosclerotic Cardiovascular Disease.
K Karmali, et al.
JACC 2014; 64:959-968
Acute Kidney Injury After CABG Versus PCI: An Observational Study Using 2 Cohorts.
T Chang, et al.
JACC 2014; 64:985-994
Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease.
D Angiolillo, et al.
JACC 2014; 64:1005-1014
In Vivo Imaging of Enhanced Leukocyte Accumulation in Atherosclerotic Lesions in Humans.
F van der Valk, et al.
JACC 2014; 64:1019-1029
Temporal Trends in the Population Attributable Risk for Cardiovascular Disease: The Atherosclerosis Risk in Communities Study.
S Cheng, et al.
Circ 2014; 130:820-828
30-Year Mortality After Venous Thromboembolism: A Population-Based Cohort Study.
K Søgaard, et al.
Circ 2014; 130:829-836
Chronic Inflammatory Disorders and Risk of Type 2 Diabetes Mellitus, Coronary Heart Disease, and Stroke: A Population-Based Cohort Study.
A Dregan, et al.
Circ 2014; 130:837-844
Effect of Reversible Intermittent Intra-Abdominal Vagal Nerve Blockade on Morbid Obesity: The ReCharge Randomized Clinical Trial.
S Ikramuddin, et al.
JAMA 2014; 312:915-922
Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults: A Meta-analysis.
B Johnston, et al.
JAMA 2014; 312:923-933
Comparison of Risk of Acute Kidney Injury After Primary Percutaneous Coronary Interventions With the Transradial Approach Versus the Transfemoral Approach (from the PRIPITENA Urban Registry).
B Cortese, et al.
AJC 2014; 114:820-825
Inflammation and Neovascularization Intertwined in Atherosclerosis: Imaging of Structural and Molecular Imaging Targets.
U Sadat, et al.
Circ 2014; 130:786-794

Poll Archives
Shao-Liang Chen, MD, et al.
| Watch CardioTube Interview
Samir R. Kapadia, MD
| Watch CardioTube Interview
RIBS IV Clinical Trial
Fernando Alfonso MD, PhD
| Watch CardioTube Interview
Gregg W. Stone, MD
| Watch CardioTube Interview
Eric J. Dippel, MD
| Watch CardioTube Interview
Renal artery denervation with a new simultaneous multi-electrode catheter for treatment of resistant hypertension: 12-month update from the first-in-man study
Robert Whitbourn, MD, et al.
SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: Post Hoc Analyses of 12-Month Results
Deepak L. Bhatt, MD, MPH, et al.
SYMPLICITY HTN-3: Analysis of the African-American and Non-African American Populations
John M. Flack, MD, et al.
Preclinical Insights Into the Optimal Ablation Location for Renal Denervation Procedures
Robert J. Melder, ScD
Two-Year Clinical Results of OPTIMIZE Trial
Fausto Feres, MD, PhD
Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Compared with Surgical Aortic Valve Replacement in High Risk Patients
Matthew R. Reynolds, MD
Multi-Vessel Versus Single-Vessel Treatment with Resolute Zotarolimus Eluting Stent in the RESOLUTE Global Clinical Program
Ganesh Manoharan, MD
Percutaneous Coronary Intervention of Small Vessels in the RESOLUTE Global Clinical Program: The Impact of Diabetes Mellitus
Milan Chag, MD
Percutaneous Coronary Intervention of Very Small Vessels in the RESOLUTE Global Clinical Program
Antonio Serra, MD
Patrick W. Serruys, MD
Randomized CTO-IVUS study
Yangsoo Jang, MD, PhD
ISAR-CLOSURE Randomized Trial
Stefanie Schupke , MD, et al.
P. Cervinka, MD, et al.
Axel Linke, MD , et al.
Two-Year Results From the CoreValve US Pivotal Trial
Steven J. Yakubov, MD
Katrin A. Fiedler, MD, et al.
SECURITY Randomized Clinical Trial
Antonio Colombo, MD
Yaling Han, MD
TRANSLATE-ACS Investigators
The IN.PACT Global Clinical Study
Gary M. Ansel, MD
1-year Results from the IN.PACT SFA II Trial
Adam C . Salisbury, MD, et al.
Serban Puricel, MD, et al.
I-LOVE-IT 2 Trial
Bo Xu, MD

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD

Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2013 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2014, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb